Free Trial
NYSE:LLY

Eli Lilly and Company (LLY) Stock Price, News & Analysis

$922.39
-1.32 (-0.14%)
(As of 02:52 PM ET)
Today's Range
$921.98
$932.60
50-Day Range
$772.14
$960.02
52-Week Range
$516.57
$972.53
Volume
900,817 shs
Average Volume
3.03 million shs
Market Capitalization
$876.64 billion
P/E Ratio
135.85
Dividend Yield
0.56%
Price Target
$977.35

Eli Lilly and Company MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.84 Rating Score
Upside/​Downside
5.5% Upside
$977.35 Price Target
Short Interest
Healthy
0.74% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.25
Upright™ Environmental Score
News Sentiment
0.62mentions of Eli Lilly and Company in the last 14 days
Based on 68 Articles This Week
Insider Trading
Selling Shares
$591.47 M Sold Last Quarter
Proj. Earnings Growth
45.36%
From $16.49 to $23.97 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.35 out of 5 stars

Medical Sector

132nd out of 927 stocks

Pharmaceutical Preparations Industry

55th out of 425 stocks

LLY stock logo

About Eli Lilly and Company Stock (NYSE:LLY)

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

LLY Stock Price History

LLY Stock News Headlines

Galicia, Spain; June 8, 2020 : Smart phone showing Merck logo on screen and pills and syringe on blue background
Is Merck Stock Undervalued After Its Colossal Earnings Growth? (LLY)
Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant?
A lab technician prepares DNA samples for analysis at Complete Genomics in San Jose, Calif
Congress targets Chinese influence in health tech. It could come with tradeoffs
A San Jose-based biotechnology company that helps doctors detect genetic causes for cancer is among those that could be cut out of the U.S. market over ties to China
Prepare for a Recession Unlike Any Other
Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.
Photo of a couple placing a soft down in their living room, sofa at an upward angle stymbolizing rising stock prices.
Invest While You Can: Pullbacks on These 3 Stocks Won’t Last Long
Three stocks stand out for investors to consider as they recently had big selloffs. There are fundamental reasons to believe that these discounts won't last
weight loss injection with measuring tape Eli Lilly
Eli Lilly’s Path to the Next Trillion Market Capitalization
Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.
In this photo The logo of Merck and Co, Inc.Merck is an American multinational pharmaceutical company
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why (LLY)
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates,
Eli Lilly Gets FDA Approval for Eczema Treatment Ebglyss
Prepare for a Recession Unlike Any Other
Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.
3 Stocks to Buy and Hold Forever
US FDA approves Eli Lilly's eczema drug
See More Headlines
Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2024
Ex-Dividend for 9/10 Dividend
8/15/2024
Dividend Payable
9/10/2024
Today
9/16/2024
Next Earnings (Estimated)
11/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
53245710
Employees
43,000
Year Founded
1876

Price Target and Rating

Average Stock Price Target
$977.35
High Stock Price Target
$1,125.00
Low Stock Price Target
$710.00
Potential Upside/Downside
+5.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.84
Research Coverage
19 Analysts

Profitability

Net Income
$5.24 billion
Pretax Margin
23.09%

Debt

Sales & Book Value

Annual Sales
$34.12 billion
Cash Flow
$7.68 per share
Book Value
$11.44 per share

Miscellaneous

Free Float
949,169,000
Market Cap
$881.05 billion
Optionable
Optionable
Beta
0.42

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

  • Eli Lilly and Co reported an impressive quarterly earnings data, surpassing the consensus estimate by a significant margin, indicating strong financial performance.
  • The company has a high return on equity of 67.52%, showcasing efficient utilization of shareholder funds to generate profits.
  • Insider transactions show major shareholders selling shares at a high price, suggesting confidence in the company's future growth prospects.
  • Eli Lilly and Co has a stable dividend payout ratio of 76.58%, providing investors with a consistent income stream.
  • Institutional investors have been increasing their stakes in the company, indicating confidence in its long-term potential.

Cons

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

  • The company's debt-to-equity ratio of 1.74 is relatively high, indicating a higher level of financial leverage which may pose risks during economic downturns.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 10, 2024. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

LLY Stock Analysis - Frequently Asked Questions

How have LLY shares performed this year?

Eli Lilly and Company's stock was trading at $582.92 at the beginning of 2024. Since then, LLY shares have increased by 58.9% and is now trading at $926.11.
View the best growth stocks for 2024 here
.

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) released its quarterly earnings results on Thursday, August, 8th. The company reported $3.92 EPS for the quarter, beating analysts' consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a trailing twelve-month return on equity of 67.52% and a net margin of 18.86%.

Does Eli Lilly and Company have any subsidiaries?

The following companies are subsidiaries of Eli Lilly and Company: Protomer Technologies, Prevail Therapeutics Inc., Disarm Therapeutics, Disarm Therapeutics, Dermira, Loxo Oncology, CoLucid Pharmaceuticals, and more.

Who are Eli Lilly and Company's major shareholders?

Top institutional investors of Eli Lilly and Company include Primecap Management Co. CA (2.06%), Legal & General Group Plc (0.75%), Bank of New York Mellon Corp (0.69%) and Dimensional Fund Advisors LP (0.38%). Insiders that own company stock include Lilly Endowment Inc, Jackson P Tai, Anne E White, Patrik Jonsson, Johna Norton, Alonzo Weems, Donald A Zakrowski, Acquisition Corp Kearny, Marschall S Runge and Ilya Yuffa.
View institutional ownership trends
.

How do I buy shares of Eli Lilly and Company?

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Eli Lilly and Company own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eli Lilly and Company investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY) and Walt Disney (DIS).

This page (NYSE:LLY) was last updated on 9/16/2024 by MarketBeat.com Staff

From Our Partners